Precision medicine

Dr. Cecil Lynch, chief medical information officer at Accenture, discusses his upcoming HIMSS23 lecture on genomics' potential impact on patient care and the importance of examining genetic information and its relationship to comorbidities.

DenovAI will create an AI-powered platform to discover potential antibodies from scratch, then suggest which ones can be used as effective drugs.

A look ahead with Judy Jiao, CIO of National Government Services, who also gives insights on precision medicine advancements and more.

Elena Viboch, partner at General Catalyst, discusses her predictions for biotech and health tech investing and how startups can grow in a more constrained economic environment.

The AI-backed genomic and clinical data company announced it had laid off about 250 workers in August.

The multinational pharma company will now be able to access Tempus' de-identified patient data.

Alphabet's life science arm also announces the company's founder Andy Conrad will step down as CEO. Current president Stephen Gillett will take on the role in January.

The layoffs represent 13% of the AI-backed genomic and clinical data company's workforce.

Precision medicine is entering the mainstream, from genetic insights informing a range of specialties to primary care using pharmacogenomics, according to Dr. Joel Diamond of 2bPrecise.

Also: Precision oncology platform OncoHost scores $35 million, home care startup Reverence emerges from stealth with $9.5 million and pediatric behavioral health startup Handspring Health completes a $6.2 million seed round.